Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Van Dam

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Gynecologic Oncology|January 1, 1992
Carcinoma in episiotomy scarsP A Van Dam, L Irvine, D G Lowe, et al.
Journal of Clinical Pathology|February 1, 1995
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breastP Hellemans, P A van Dam, M Geyskens, et al.
Journal of Clinical Pathology|October 1, 1990
Tissue preparation for simultaneous flow cytometric quantitation of tumour associated antigens and DNA in solid tumoursP A van Dam, J V Watson, D G Lowe, et al.
Cancer|July 1, 1991
Multi-parameter flow cytometric quantitation of the expression of the tumor-associated antigen SM3 in normal and neoplastic ovarian tissues. A comparison with HMFG1 and HMFG2P A van Dam, D G Lowe, J V Watson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 27, 2003
Intraoperative sentinel node identification with Technetium-99m-labeled nanocolloid in patients with cancer of the uterine cervix: a feasibility studyP A van Dam, J Hauspy, T Vanderheyden, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 19, 2016
Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?P A van Dam, V C N van Dam, S Altintas, et al.
Facts, Views & Vision in Obgyn|March 16, 2016
The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectivesK Papadmitriou, X B Trinh, S Altintas, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 7, 2016
Current and future role of circulating tumor cells in patients with epithelial ovarian cancerC Van Berckelaer, A J Brouwers, D J E Peeters, et al.
Journal of Clinical Pathology|October 1, 1989
Prognostic value of prostaglandin F2 alpha concentrations in breast carcinomaP A van Dam, I B Vergote, G M Laekeman, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1991
Prostacyclin/thromboxane ratio in human breast cancerI B Vergote, P A van Dam, G M Laekeman, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Gynecologic Oncology|January 1, 1992
Carcinoma in episiotomy scarsP A Van Dam, L Irvine, D G Lowe, et al.
Journal of Clinical Pathology|February 1, 1995
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breastP Hellemans, P A van Dam, M Geyskens, et al.
Journal of Clinical Pathology|October 1, 1990
Tissue preparation for simultaneous flow cytometric quantitation of tumour associated antigens and DNA in solid tumoursP A van Dam, J V Watson, D G Lowe, et al.
Cancer|July 1, 1991
Multi-parameter flow cytometric quantitation of the expression of the tumor-associated antigen SM3 in normal and neoplastic ovarian tissues. A comparison with HMFG1 and HMFG2P A van Dam, D G Lowe, J V Watson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 27, 2003
Intraoperative sentinel node identification with Technetium-99m-labeled nanocolloid in patients with cancer of the uterine cervix: a feasibility studyP A van Dam, J Hauspy, T Vanderheyden, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 19, 2016
Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?P A van Dam, V C N van Dam, S Altintas, et al.
Facts, Views & Vision in Obgyn|March 16, 2016
The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectivesK Papadmitriou, X B Trinh, S Altintas, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 7, 2016
Current and future role of circulating tumor cells in patients with epithelial ovarian cancerC Van Berckelaer, A J Brouwers, D J E Peeters, et al.
Journal of Clinical Pathology|October 1, 1989
Prognostic value of prostaglandin F2 alpha concentrations in breast carcinomaP A van Dam, I B Vergote, G M Laekeman, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1991
Prostacyclin/thromboxane ratio in human breast cancerI B Vergote, P A van Dam, G M Laekeman, et al.
Pageof 5